Effects of natalizumab on work ability in patients with relapsing-remitting multiple sclerosis: results from the WANT observational study

被引：0
|
作者：
Capra, R. [1 ]
De Rossi, N. [1 ]
Masera, S. [2 ]
Zipoli, V. [2 ]
Morra, V. Brescia [3 ]
Mirabella, M. [4 ]
Patti, F. [5 ]
机构：
[1] Multiple Sclerosis Ctr, Spedali Civili Brescia, Montichiari, Italy
[2] Biogen, Cambridge, MA USA
[3] Univ Federico II, Dept Neurosci & Reprod & Odontostomatol Sci, Naples, Italy
[4] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, Multiple Sclerosis Ctr, Rome, Italy
[5] Univ Catania, Multiple Sclerosis Ctr, Neurosci Sect, DANA Dept, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P558
引用
收藏
页码：264 / 265
页数：2
相关论文
共 50 条
  • [11] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [12] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [13] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [14] Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
    Sangalli, F.
    Moiola, L.
    Bucello, S.
    Annovazzi, P.
    Rizzo, A.
    Radaelli, M.
    Vitello, G.
    Grimaldi, L. M. E.
    Ghezzi, A.
    Martinelli, V.
    Comi, G.
    [J]. NEUROLOGICAL SCIENCES, 2011, 31 : S299 - S302
  • [15] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
    Baroncini, D.
    Ghezzi, A.
    Stefanin, C.
    Zaffaroni, M.
    Annovazzi, P.
    Baldini, S.
    Comi, G.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
  • [16] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [17] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Doehler, N.
    Mueller, S.
    Vehoff, J.
    Galovic, M.
    Tettenborn, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
  • [18] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
    Alroughani, R.
    Al Hashel, J.
    Thussu, A.
    Ahmed, S. F.
    [J]. MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
  • [19] A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
    Trojano, Maria
    Ramio-Torrenta, Lluis
    Grimaldi, Luigi M. E.
    Lubetzki, Catherine
    Schippling, Sven
    Evans, Karleyton C.
    Ren, Zheng
    Muralidharan, Kumar Kandadi
    Licata, Stephanie
    Gafson, Arie R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2240 - 2253
  • [20] Efficacy and safety of natalizumab treatment for relapsing-remitting multiple sclerosis: interim results of the TYSABRI® Observational Programme in Canada
    Jacques, F.
    Bhan, V.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 695 - 696
12345